

Jörg B Engel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5929181/publications.pdf>

Version: 2024-02-01

45
papers

1,570
citations

257101

24
h-index

301761

39
g-index

45
all docs

45
docs citations

45
times ranked

2211
citing authors

#	ARTICLE	IF	CITATIONS
1	Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008, 4, 33-43.	2.9	179
2	Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. <i>British Journal of Cancer</i> , 2010, 103, 693-700.	2.9	171
3	Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1405-1418.	2.0	163
4	Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 157-167.	2.9	142
5	Ovarian epithelial tumors and reproductive factors: a systematic review. <i>Archives of Gynecology and Obstetrics</i> , 2013, 287, 1187-1204.	0.8	70
6	Use of Analogs of Peptide Hormones Conjugated to Cytotoxic Radicals for Chemotherapy Targeted to Receptors on Tumors. <i>Current Drug Delivery</i> , 2011, 8, 11-25.	0.8	61
7	Targeted Therapy of Breast and Gynecological Cancers with Cytotoxic Analogues of Peptide Hormones. <i>Molecular Pharmaceutics</i> , 2007, 4, 652-658.	2.3	57
8	Human Malignant Melanomas Express Receptors for Luteinizing Hormone Releasing Hormone Allowing Targeted Therapy with Cytotoxic Luteinizing Hormone Releasing Hormone Analogue. <i>Cancer Research</i> , 2005, 65, 5857-5863.	0.4	40
9	Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 10403-10407.	3.3	40
10	Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1. <i>Cancer</i> , 2005, 104, 1312-1321.	2.0	39
11	Potential of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 1943-1946.	3.3	39
12	Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins. <i>Endocrine-Related Cancer</i> , 2005, 12, 999-1009.	1.6	36
13	Receptors for Luteinizing Hormone Releasing Hormone Expressed on Human Renal Cell Carcinomas Can Be Used for Targeted Chemotherapy with Cytotoxic Luteinizing Hormone Releasing Hormone Analogues. <i>Clinical Cancer Research</i> , 2005, 11, 5549-5557.	3.2	36
14	Inhibition of Growth of Experimental Human Endometrial Cancer by an Antagonist of Growth Hormone-Releasing Hormone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 3614-3621.	1.8	35
15	Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro. <i>Oncology Reports</i> , 2012, 28, 2023-2028.	1.2	35
16	Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1. <i>Archives of Gynecology and Obstetrics</i> , 2014, 289, 141-147.	0.8	35
17	Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207. <i>European Journal of Cancer</i> , 2005, 41, 2196-2202.	1.3	31
18	Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207. <i>Fertility and Sterility</i> , 2005, 83, 1125-1133.	0.5	29

#	ARTICLE	IF	CITATIONS
19	Presurgical short term treatment of uterine fibroids with different doses of cetrorelix acetate: A double-blind, placebo-controlled multicenter study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2007, 134, 225-232.	0.5	29
20	Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 273-279.	1.1	29
21	Macrophage migration inhibitory factor expression in cervical cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 651-657.	1.2	29
22	Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylation. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2008, 141, 64-69.	0.5	28
23	Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist Cetrorelix with growth inhibition. <i>International Journal of Oncology</i> , 2009, 35, 789-96.	1.4	26
24	Induction of programmed cell death by inhibition of AKT with the alkylphosphocholine perifosine in in vitro models of platinum sensitive and resistant ovarian cancers. <i>Archives of Gynecology and Obstetrics</i> , 2011, 283, 603-610.	0.8	26
25	Effective Inhibition of Experimental Human Ovarian Cancers with a Targeted Cytotoxic Bombesin Analogue AN-215. <i>Clinical Cancer Research</i> , 2005, 11, 2408-2415.	3.2	23
26	Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 10628-10633.	3.3	21
27	Effects of lobaplatin as a single agent and in combination with TRAIL on the growth of triple-negative p53-mutated breast cancers in vitro. <i>Anti-Cancer Drugs</i> , 2012, 23, 426-436.	0.7	21
28	Targeted chemotherapy with cytotoxic bombesin analogue AN-215 can overcome chemoresistance in experimental renal cell carcinomas. <i>Cancer</i> , 2005, 104, 2266-2274.	2.0	17
29	Immune escape of AKT overexpressing ovarian cancer cells. <i>International Journal of Oncology</i> , 2013, 42, 1630-1635.	1.4	13
30	Experimental therapy of human endometrial cancers with a targeted cytotoxic bombesin analog AN-215: Low induction of multidrug resistance proteins. <i>European Journal of Cancer</i> , 2005, 41, 1824-1830.	1.3	12
31	Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238. <i>International Journal of Cancer</i> , 2005, 114, 831-835.	2.3	11
32	Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS-126 in models of ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2015, 291, 131-141.	0.8	7
33	Analysis of Clusterin and Clusterin Receptors in the Endometrium and Clusterin Levels in Cervical Mucus of Endometriosis. <i>Reproductive Sciences</i> , 2016, 23, 1371-1380.	1.1	7
34	Effects of an Antagonistic Analog of Growth Hormone-Releasing Hormone on Endometriosis in a Mouse Model and In Vitro. <i>Reproductive Sciences</i> , 2017, 24, 1503-1511.	1.1	7
35	Inhibin A/B in HMG or recombinant FSH ovarian stimulation with cetrorelix medication. <i>Reproductive BioMedicine Online</i> , 2001, 3, 104-108.	1.1	5
36	Search for novel therapies for triple negative breast cancers (TNBC): analogs of luteinizing hormone-releasing hormone (LHRH) and growth hormone-releasing hormone (GHRH). <i>Hormone Molecular Biology and Clinical Investigation</i> , 2012, 9, 87-94.	0.3	4

#	ARTICLE	IF	CITATIONS
37	Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS 126 in models of triple-negative breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 905-914.	1.2	4
38	The GnRH antagonist cetrorelix: established indications and future potential. <i>Expert Review of Obstetrics and Gynecology</i> , 2007, 2, 431-440.	0.4	3
39	LHRH Analogs. , 2013, , 531-540.		3
40	Inhibin B on the day of HCG-administration is a predictive factor for failure in assisted reproduction cycles. <i>Archives of Gynecology and Obstetrics</i> , 2003, 268, 278-280.	0.8	2
41	Tubulin inhibitor AEZS 112 inhibits the growth of experimental human ovarian and endometrial cancers irrespective of caspase inhibition. <i>Oncology Reports</i> , 2009, 22, 361-7.	1.2	2
42	Cervical endometriosis associated with malignant pleural mesothelioma mimicking cervical cancer – Occam’s razor or the “third man”. <i>Fertility and Sterility</i> , 2011, 95, 1787.e5-1787.e7.	0.5	1
43	GHRH-antagonists in TNBC. <i>Oncotarget</i> , 2015, 6, 1898-1899.	0.8	1
44	Analogs of Luteinizing Hormone-Releasing Hormone (LHRH) in Cancer. , 2006, , 421-427.		1
45	Analysing Molecular Mechanism Related to Therapy- Resistance in In-vitro Models of Ovarian Cancer. , 2016, , .		0